In nature, microorganisms prefer to reside in structured microbial communities, termed biofilms, rather than as
free-floating planktonic cells. Advantageous for the microorganisms, but disadvantageous for human health, is the
increased resistance/tolerance of the biofilm cells to antimicrobial treatment. In clinically relevant biofilms, Candida
albicans is one of the most frequently isolated microorganisms in biofilms. This review primarily elaborates on the
activity of the currently used antimycotics against Candida biofilms, the potential of antifungal lock therapy and sheds
more light on new promising compounds resulting from the gradual shift of anti-biofilm research activities to natural
products, plants and their extracts.